BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24381225)

  • 1. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
    Stoddart A; Fernald AA; Wang J; Davis EM; Karrison T; Anastasi J; Le Beau MM
    Blood; 2014 Feb; 123(7):1069-78. PubMed ID: 24381225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.
    Stoddart A; Wang J; Fernald AA; Karrison T; Anastasi J; Le Beau MM
    Blood; 2014 Jan; 123(2):228-38. PubMed ID: 24264229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
    Qian Z; Joslin JM; Tennant TR; Reshmi SC; Young DJ; Stoddart A; Larson RA; Le Beau MM
    Chem Biol Interact; 2010 Mar; 184(1-2):50-7. PubMed ID: 19958752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
    Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
    Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.
    Joslin JM; Fernald AA; Tennant TR; Davis EM; Kogan SC; Anastasi J; Crispino JD; Le Beau MM
    Blood; 2007 Jul; 110(2):719-26. PubMed ID: 17420284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
    Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
    Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy.
    Stoddart A; Fernald AA; Davis EM; McNerney ME; Le Beau MM
    Exp Hematol; 2022 Nov; 115():54-67. PubMed ID: 35995095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y; Cook JR
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
    Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
    EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms.
    Stoddart A; Wang J; Fernald AA; Davis EM; Johnson CR; Hu C; Cheng JX; McNerney ME; Le Beau MM
    Blood Cancer Discov; 2020 Jul; 1(1):32-47. PubMed ID: 32924016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploinsufficiency of Apc leads to ineffective hematopoiesis.
    Wang J; Fernald AA; Anastasi J; Le Beau MM; Qian Z
    Blood; 2010 Apr; 115(17):3481-8. PubMed ID: 20065296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.